Product Development New England, Naveris, NavDx, minimal residual disease monitoring in head and neck cancer
Hartford, CT
Joined September 2018
- Tweets14.3K
- Following5.3K
- Followers1.6K
- Likes55.5K
Pat Adams retweeted
TKIs in pregnancy for lung cancer: 27 pregnancies, 96.3% live births, 80.8% of mothers responded. They can be considered in selected cases with a multidisciplinary team 🤰🏽🫁 Congrats to Dr. Noseda and Dr. Imbimbo for leading it!
doi.org/10.1007/s40265-026-0…
Pat Adams retweeted
Ovary – Changes to WHO Classification (6th edition, 2026)
Serous borderline ovarian tumors:
The terms “microinvasion” and “microinvasive” are no longer recommended
What was previously called microinvasion (single cells and clusters of cells with eosinophilic cytoplasm and low-grade nuclear features) has no clinical significance (see pic 2). It can be mentioned in a comment if desired; Dr. Gilks previously reported it but no longer does
What was previously called microinvasive carcinoma represents small foci of low-grade serous carcinoma (see pic 3). Report the size and extent of these foci and diagnose them as a small focus of low-grade serous carcinoma arising in a serous borderline tumor
Dr. Gilks. Gynecologic Pathology Masterclass 2026
#USCAP #pathology #pathX
Pat Adams retweeted
Could #filter #paper help scale #HPV self-sampling?
🧪 90.9% agreement with clinician-collected samples
🙋 75% preferred self-collection
⚠️ Protocol optimization needed to improve sensitivity and reduce invalid results
Read the study here: bit.ly/4iqUmUS
@pedroramirezMD @IJGConline @IJGCfellows @GynMe4 @RParejaGineOnco @lchiv4 @annafagottimd @HousseinELHAJJ3 @AinhoaMada @Suvidyasingh20 @ohadfeld
#IJGConline #Research #Prevention #Treatment #Diagnostic #GynCancer #GynOnc #WomenHealth #SoMe #SoMe4GynOnc
Pat Adams retweeted
Really encouraging data. And trop2 is ubiquitous except for NEC and sarcomatoid. Exciting data for challenge!
SAC-TMT + pembro shows 68% response rates in metastastic bladder cancer #ESMO2026 . Trofuse-55 explores this combination in bladder sparing approaches in a randomized phase 3. The triplet with EVP seems a justified research randomised question. Triplet data from yesterday showed 81% RRs. @OncoAlert
Pat Adams retweeted
The 2026 U.S. measles total so far exceeds 2x the total for 2025, which was itself 8x the total for 2024.
Pat Adams retweeted
Are our pathology guidelines keeping pace with reality?
📖 A thought-provoking proposal to make diagnostic criteria practical, accessible and globally applicable in this excellent paper by the authors - Philippe Benjamin Stephenson, Olaleke Folaranmi, José Jiménez Heffernan, and Sanjay Mukhopadhyay, published in the BMJ Journal of Clinical Pathology.
Three powerful messages:
🔹 Make criteria feasible across resource settings
🔹 Focus on what truly impacts diagnosis and treatment
🔹 Guideline panels should include community pathologists and represent the global community of pathologists
The best guidelines should not just define what is ideal—they should help every pathologist make the best possible diagnosis with the resources available.
Link to the full paper here bit.ly/4cvgo6K
Pat Adams retweeted
What is your type ??!!
Mine is bit of 1(not an expert, but no choice than to rely on morphology ) ; more of 7( being a literary person, need to check the language & spellings & description anywhere) and 10( to get the mental peace back ) 😄
#pathology #pathologists #pathtwitter
Pat Adams retweeted
Sending federal election monitors to New Haven is more about intimidating voters than protecting election integrity. There is no evidence of fraud or illegality—not a scintilla—that justifies this overreaching by a DOJ that should be pursuing real wrongdoing.
Pat Adams retweeted
#Weekend_Review : Venetoclax for Rx of #ALL
Venetoclax is increasingly being explored across B-ALL and T-ALL, from frontline therapy to relapsed/refractory disease.
What have we learned so far, and where might it fit?
1/10
First, why venetoclax?
BCL-2 is a key anti-apoptotic protein. Venetoclax selectively inhibits BCL-2, lowering the threshold for mitochondrial apoptosis.
But the important concept is:
BCL-2 expression ≠ BCL-2 dependence.
That distinction may help explain both sensitivity and resistance.
Pat Adams retweeted
🧬🔬 MOSAIC is out in Genome Medicine!
The Multi-Omics Spatial Atlas in Cancer: >2,700 tumor samples across ≥10 tumor types, generated in standardized labs at 5 founding partners (CHUV, Charité, UK Erlangen, Gustave Roussy, Pitt) together with Owkin (@OwkinScience)
📦 6 modalities from ONE FFPE block:
• H&E whole slide images
• Visium CytAssist spatial transcriptomics
• snRNA-seq (Chromium Flex)
• Bulk RNA-seq
• Whole exome sequencing
• Curated clinical data
🔓 MOSAIC Window, the first open release: 60 patients with bladder cancer, ovarian cancer, GBM, DLBCL and mesothelioma, available via EGA.
Key findings:
🧩 Most tumors harbor ≥2 genomically, spatially and transcriptionally distinct malignant subsets (pan-cancer median 3, GBM median 6)
🫧 Bladder cancer shows the highest inter-patient heterogeneity of all indications
🔗 Tumor cell signaling tracks with its neighborhood: TGF-β ↔ fibroblasts, VEGF and JAK-STAT ↔ macrophages
🧬 Copy number profiles do not always dictate transcriptomic state, pointing to passenger alterations
4 case studies with a therapeutic angle:
🎯 Mesothelioma: an inflamed, MET-active niche with high anti-PD-1 signature next to an immune-cold niche in the same tumor
🎯 Bladder: squamous/keratinizing vs. proliferative subsets independent of CN background; CEACAM5/6 confined to nest cores, relevant for ADC targeting
🎯 Ovarian: HRD signature restricted to one subset, suggesting heterogeneous PARPi sensitivity
💡 Bulk profiling averages out exactly the niches that may decide treatment response.
Proud that Erlangen Pathology is a founding partner. Thanks to all patients, the Owkin team and every co-author 🙏.
This is just the first step on a great journey with MOSAIC
#PathTwitter #SpatialTranscriptomics #SingleCell #Multiomics #DigitalPathology #AIinPathology #PrecisionOncology #TumorHeterogeneity #BladderCancer #OpenData
📄 doi.org/10.1186/s13073-026-0…
Pat Adams retweeted
Some of my colleagues think things will just “blow over” and “it’s not that bad”. This @nytimes article starts to reveal the deep wounds this govt has (self)inflicted on the research engines that have driven US innovation. All I can say is VOTE next week! nytimes.com/2026/10/31/clima…
Pat Adams retweeted
A truly disturbing report on the administration's effort to politicize and dismantle the scientific infrastructure in the US. This should be concerning to all who care about the health of their loved ones, all businesses concerned with the welfare of their employees and their future products, and all those who care about the long term economic and military strength of America.
Free link below:
nytimes.com/2026/10/31/clima…
Pat Adams retweeted
Most grateful to Nature Immunology for highlighting our recent discovery of receptor-free TLR signal transduction
@NatImmunol
nature.com/articles/s41590-0…
Pat Adams retweeted
Disappointing catch to the announcement about interceptors going to Ukraine—delivery in a few years. Facing a hideously harsh winter & searing hardship from Russian bombs, Ukraine urgently needs air defense.
A strong decision by the U.S. State Department – authorizing Ukraine’s purchase of Patriot interceptors to counter Russian ballistic missiles. Five hundred PAC-3 interceptors is a substantial number, and very soon – this winter – they COULD make for a highly effective defense package. However, it has been stipulated that deliveries may begin ONLY IN A FEW YEARS. We are asking our American partners to find a solution for the time when there is a real danger and a real need to use PAC-3 interceptors.
Right now, the Russians are attacking our energy infrastructure every single day. In just these past two weeks of October, there have already been more than 30 Russian strikes on critical parts of our power grid. It is right now, even before the beginning of winter, that Putin has started carrying out his operation to attack the systems that sustain life in our cities and communities. The targets are electricity, heating, water supplies, bridges, and life in our cities in general.
We did ask our American partners to provide Ukraine with a winter support package – at a rate of 100 Patriot interceptors per month. Five hundred missiles would be enough to protect our skies over the coming months – precisely when it is so important for Ukraine to be in a strong position in negotiations and for Russia NOT to succeed in breaking life in Ukrainian cities and communities.
The United States, our European partners, and other partners around the world have sufficient stocks of PAC-3 interceptors in their warehouses. Providing them to Ukraine right now – in the winter of 2026–2027 – and replenishing our partners’ arsenals LATER, in THE FOLLOWING YEARS, through this production already contracted and paid for by Ukraine and our partners would be the right approach. And it is entirely feasible.
We are grateful to President Trump. Importantly, we recently discussed PAC-3 interceptors with Secretary of State Marco Rubio. Ukraine is grateful to the U.S. State Department and the U.S. Administration overall for granting this authorization. But we are asking for decisions that can guarantee the protection of lives not the day after tomorrow or sometime later, but at the very moment the threat is there – when Russia is killing and destroying. I thank everyone who stands with Ukraine!
state.gov/releases/bureau-of…
Pat Adams retweeted
Thrilled to share JEEPERS, our new study in @naturemethods on improving #cfDNA methylation profiling by correcting jagged-end errors. Led by @RuiwrWang with @max_diehn & our @StanfordMed team. #LiquidBiopsy 1/6
nature.com/articles/s41592-0…
ALT JEEPERS workflow: quantify and correct jagged ends, extract methylation features, genotype mutations, and compare allele-specific methylation for tumor-burden and cell-type analyses.
Pat Adams retweeted
Mass photometry uses light to weigh individual molecules. I think it’s really compelling and useful.
If you wanted to weigh a protein, for example, you shine light at it, and electrons in the protein respond by scattering some of that light. The amplitude of the scattered light wave is approximately proportional to molecular mass, meaning that larger proteins produce a "stronger" signal than smaller proteins.
Special microscopes can detect these tiny, tiny signals by combining light scattered by a protein with light reflected from the glass slide beneath it. The two light waves interfere, producing a small change in brightness. Researchers calibrate those measurements using proteins with known masses.
Now, usually, mass photometry weighs a molecule as it falls on top of glass. But for this paper, they describe a method to keep weighing the same molecule and watch its mass change as other molecules attach and detach, in real-time.
Basically, they attached individual proteins to small patches of a lipid membrane, so each protein could move a little bit, but couldn’t drift out of view. They then measured the mass of that protein 497 times PER SECOND over the span of an entire hour. Every time the protein binds to anything (like an antibody, or its receptor, or a small molecule), the binding event shows up as a little spike in the data.
So with the SARS-CoV-2 spike protein, for example, they could follow its mass rising and falling as the ACE2 receptor attached and detached. They measured how long the two stayed bound together, also: 64 seconds on average. They also watched antibodies attach one after another, producing up to three distinct increases in mass, matching the spike’s three binding sites. Really beautiful biophysics.
Pat Adams retweeted
Very happy to share newest online publication in JAMA Oncology @JAMAOnc, "FGFR Alterations in Bladder Cancer- From Molecular Pathogenesis to Precision Oncology," written by Dr. Katrina Collins @katcollmd
In this review, we examine how FGFR biology is reshaping the molecular classification and precision management of patients with bladder cancer. We highlight the central role of FGFR3 alterations and the fast-growing range of molecular biomarker testing at every stage of disease. We discuss comprehensive genomic profiling, liquid biopsy (including urine-based molecular testing), and emerging molecular residual disease (MRD) assessment. We also cover how each is used in diagnosis, treatment selection, surveillance, and disease monitoring.
On the therapeutic front, erdafitinib has established FGFR-directed precision therapy in advanced urothelial carcinoma. Combination approaches, intravesical FGFR-directed treatments, and next-generation FGFR3-selective inhibitors are extending this strategy into new clinical settings. Emerging technologies, including AI-assisted histopathology and integrated multi-omic biomarkers, may further refine patient selection.
Read the full article: doi.org/10.1001/jamaoncol.20…
Pat Adams retweeted
General prediction of T cell receptor antigen specificity from sequence using AlphaFold 3
science.org/doi/10.1126/scia…
Pat Adams retweeted
🚀 Introducing #PathCowork: Learning from real-world pathology practice to build AI copilots!
Most pathology AI learns what pathologists conclude, but rarely how they actually practice.
Diagnosis is more than recognizing patterns. It requires knowing where to look, when to zoom in, how to connect evidence, and what to examine next.
Using our #TissueLab (tissuelab.org) platform, we captured synchronized eye gaze, voice narration, and slide navigation from 16 pathologists across 48 sessions and over 1,000 minutes of real-world diagnostic examinations at @PennPathLabMed, under an active IRB.
We explored whether AI could learn directly from this clinical diagnostic expertise.
🔍 Learning where to look: Visual grounding improved from 5.6% to 52.2%, enabling AI to better locate diagnostic features in tissue images.
🧭 Learning how to examine: Our agents outperformed Claude Code and Codex across 5 pathology tasks, running ~5× faster at ~10× lower cost.
💻 We are releasing PathCowork-1T and PathCowork-27B, along with code and model weights!
Our vision is to turn everyday clinical practice into a continuous source of learning for medical AI.
The next breakthrough may come not just from scaling models and datasets, but from fundamentally rethinking what AI learns and how it learns.
📄 Paper: arxiv.org/abs/2610.39441
💻 Code & weights: github.com/zhihuanglab/PathC…
#DigitalPathology #MedicalAI #AgenticAI
@PennPathLabMed @PennMedicine